Fig. 1
Immunogenicity of PD03 in PLP-α-syn mice, antibody binding in the brain, and gait analysis. a The plasma levels of antibodies binding to human α-syn after PD03 immunotherapy reached a high level at week 6 and remained stable thereafter. b ELISA-based competition assay demonstrating the competitive binding of PD03 antibodies to α-syn monomers and fibrils. c Percentage of area positive for IgG binding in the brains of vehicle- and PD03-treated PLP-α-syn mice (two-tailed t-test, nvehicle = 8, nPD03 = 10, t16 = 6.742, ***P < 0.0001). d DigiGait analysis of wild-type controls, and PLP-α-syn mice receiving vehicle or PD03. Data were analyzed with one-way ANOVA followed by Bonferroni’s post-hoc test (*P < 0.05), **P < 0.01